Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.

ABSTRACT:

Background

The recommended doxorubicin (DOX) dose for small dogs is 1 mg/kg. Recent data suggest that DOX-induced gastrointestinal (GI) toxicosis can be reduced with maropitant treatment.

Objectives

To investigate the incidence of adverse events (AEs) in small-breed dogs administered a single 25 mg/m² DOX followed by administration of maropitant (DOX25). The primary aim was to assess myelo- and GI toxicoses for 2 weeks after DOX administration. The secondary aim was to compare the incidence and grades of AEs found in the DOX25 group with a historical control group (DOX 1 mg/kg without administration of antiemetic or antidiarrheal medications).

Animals

Nineteen small-breed tumor-bearing dogs.

Methods

A prospective, observational study of tumor-bearing

SUBMITTER: Matsuyama F 

PROVIDER: S-EPMC9308424 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature